Mahesh Karande has been appointed CEO of Omega Therapeutics. Karande was most recently president and CEO of Macrolide Pharmaceuticals. His experience also includes positions at Novartis (NYSE: [[ticker:NVS]]). Cambridge, MA-based Omega, which was formed by venture capital firm Flagship Pioneering, is developing drugs based on epigenetics, the study of the biological mechanisms that turn genes on and off.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
